Resbiotic Nutrition has announced it has raised a total of $14.5 million, including a recently concluded $8 million Series A round led by major investors Sororibus Capital and Biostack Ventures.
The new funding will be used to fuel the expansion of the company's product portfolio, scale retail and e-commerce distribution and strengthen its B2B ingredient and formulations offerings.
Resbiotic is pioneering the Gut-X Axis, a science-driven platform that connects gut health to whole-body outcomes across multiple systems to address chronic health issues.
The company's flagship product, resB Lung Support, is the first clinically tested probiotic targeting the gut-lung axis for respiratory health.
Resbiotic is leveraging its Gut-X Axis platform to move beyond respiratory health into metabolic, women’s and bone health, aiming to address key areas of unmet consumer need.
"With res, we are setting a new standard in the supplement industry — products that are not only rooted in rigorous science but also accessible to people everywhere," said Dr. C. Vivek Lal, founder and CEO.
"By combining robust preclinical testing and clinical trials at the product level with a vertically integrated R&D model, we ensure our formulations deliver real, measurable benefits."
"This funding enables us to expand our Gut-X Axis portfolio, deepen our retail partnerships and meet growing consumer demand for evidence-based health solutions."
Alongside its consumer offerings, Resbiotic's B2B division is experiencing growth, driven by demand for its proprietary formulations and novel microbiome-based ingredients.
This business arm complements the company's consumer reach, creating new pathways for industry collaboration and innovation.
Resbiotic’s products are now sold nationwide in Walmart stores and through its direct-to-consumer e-commerce platform, supporting the company’s mission to make evidence-based microbiome health solutions affordable and widely accessible.